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“Community Pharmacy: Going Beyond Dispensing Pharmaceuticals” 
 
Abstract 
The aim of this study is to understand if it is possible to predict health crisis based on 
biochemical and physiological measurements made at the pharmacy, and, if needed, refer 
patients to the doctor. This would avoid emergency services and increase pharmacies’ income. 
Three pharmaceutical consultations were made, where these parameters were measured and the 
therapeutics registered. The short duration of the study (three months) and the small sample (57 
patients) did not allow to reach clear conclusions, as patients had little variation in their health. 
It was also addressed the issue of how important these consultations are for patients and results 
were positive: they considered consultations important and helpful and the majority of patients 
were willing to pay €5 or less for them. 
 
Key words: pharmacy, pharmacist, cholesterol, glycaemia, blood pressure, body mass 
index, abdominal circumference. 
1) Introduction 
In Portugal, the healthcare system struggles with problems of overuse of emergency 
services, being, in 2011, the country with higher number of visits to emergency departments 
across the 21 OECD countries (Berchet, 2015). Pharmacies can represent an important link 
between people and primary healthcare services due to their proximity to the population. The 
main goal of this study is to understand if, using pharmacies to follow patients with chronic 
conditions, it is possible to predict crisis on their health and have an early referral to treatment. 
If this hypothesis proves to be true, pharmacies could refer patients to the doctor, reducing the 
affluence to the emergency services (ES). This would be advantageous for everyone: 
pharmacists would become more integrated on the National Health Service and more valued by 
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society, pharmacies would find at consultations a new source of income if the state and/or the 
patients were willing to pay and the state would solve some of the problems related to the high 
affluence to ES and would reduce costs once treating a patient in a phase of acuteness is more 
expensive than treating them earlier. Finally, the patient would benefit because consultations 
would improve life’s quality and provide a better healthcare service. This following of patients 
may allow the pharmacist to detect a worsening of patient’s clinical situation and, either treat 
minor situations or refer major situations to the doctor.  
To conduct the study, monthly pharmaceutical consultations were implemented as part of 
the project, so that all patients could have a close and regular following of their clinical 
situation. At these consultations, patients registered all their medication and measured the 
following physiological and biochemical parameters: glycaemia, cholesterol, blood pressure 
and height/weight. The data analysis consisted on looking at patients with a change of 
medication and on making a retrospective analysis of their parameters to understand if there 
was a cause-effect relationship. If it is possible to prove a relationship between a variation on 
these parameters and a future change on medication, pharmacists could detect crisis situations 
in advance.  These consultations will be fully detailed at the section “More about biochemical 
and physiological measurements”. This study also measured how differently patients felt their 
health related quality of life (HRQOL) through the application of an EQ-5D questionnaire. This 
questionnaire is the most used generic instrument to measure HRQOL and it can be compared 
across diseases (Office of Health Economics), which is important at this study once we are 
comparing patients with different conditions. It consists on five questions, each one 
corresponding to one dimension: Mobility (MO), Personal Care (PC), Usual Activities (UA), 
Pain/Discomfort (PD) and Anxiety/Depression (AD). For each dimension, there are three levels 
of severity experienced or felt by the individual: no problems (level 1), some problems (level 
2) and extreme problems (level 3). Thus, this system allows to describe a total of 35 = 243 
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different states of health (Ferreira et al., 2013). At the end, the respondent is asked to attribute 
a punctuation based on her/his own assessment of her/his health through a visual analog scale 
from 0 (worst imaginable health state) to 100 (best imaginable health state) - EQ-VAS 
thermometer. The EQ-5D questionnaire was included in this study in order to understand if the 
changes on the values of clinical measurements and/or the changes on medication were 
reflected on the way that patients felt their own health. Three more questions were added about 
whether patients attended the doctor and what was the outcome of that consultation, so that we 
could detect if there was a change on medication (see appendix 1). Moreover, each patient’s 
pharmacotherapeutic profile was registered. This study created on patients the routine of 
consultations and the routine of talking to the pharmacist about their diseases.  
At the third and last phase of the study, it became possible to notice that no results were 
being obtained, because there were no variations on patients’ health. As it was not possible to 
extend neither the study nor the sample, it was interesting to understand patients’ opinion about 
consultations. In other words, we decided to look for the benefits of consultations other than try 
to predict sickness episodes. Thus, a final questionnaire was built to apply after the third 
consultation. This questionnaire was composed by 8 questions in which patients had to classify 
the consultation: how useful it was to understand their disease, how it made them feel about 
their disease, what changed on their daily life and how important/trustable the pharmacy and 
the pharmacist were. They also had to classify the importance of measuring each one of the 
biochemical and physiological parameters and state whether they were willing to pay for 
consultations (reasons and value) or not.  
As a pharmacist and a manager, I had a huge motivation to conduct this study. I think it is 
important that, as well as in other countries, Portuguese pharmacies are more integrated on the  
healthcare system and that the pharmacist is recognized as a healthcare professional that is 
qualified to diagnose and/or refer patients when faced with certain signs and symptoms. 
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Moreover, for regular patients, pharmacies have the history of the whole medication (that each 
doctor who the patient attends prescribes) and supplements that patients do. 
As a manager, I found important to understand how could society value the pharmacist and 
the pharmacy and what tangible and non-tangible benefits could the pharmacy have from it.  
After this study, it became very clear that the implementation of these consultations requires 
changes on the management of the pharmacy. The most crucial aspect is that an available 
pharmacist is needed and the fact that the pharmacist is making consultations has an associated 
opportunity cost, once she/he is not available for other tasks. Thus, it is not possible to have 
consultations during all business hours. It is necessary to reorganize tasks so that the fact that 
the pharmacist is on consultation does not harm the normal functioning of the pharmacy.  
Regarding the organization of this work, section 2 represents the background for the study. 
Section 3 explains the study, its procedures and results, as well as the conclusions that can be 
taken. 
2) Background 
a) The pharmacy and its community 
The pharmacy is usually the most accessible healthcare facility to patients. Therefore, 
they attend pharmacies more regularly than they attend the doctor. Traditionally, patients used 
the pharmacy to get medication (prescription and over the counter (OTC) drugs (see 
”Glossary”)) and/or to get advice for its use. This narrow definition of the role of the pharmacy 
is slowly changing (Barros et al., 2015). The proximity between the pharmacist and the 
population allied to the pharmacist’ experience with drugs (formulation, chemistry and 
pharmacology) allows building a relation of confidence, making the pharmacy a healthcare 
point where a healthcare professional can easily connect to the population. Ana Paula Martins, 
Portuguese Pharmacists Association’ President, has herself stated: “Pharmacists are 
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indispensable for the survival of the healthcare system with phenomena such as the growing of 
aging population, (…). Pharmacists are essential in preventing the disease (…)” (Ana Paula 
Martins 2016a, 2016). She also defended on an interview on a Portuguese TV channel that her 
priority is to assure that the SNS (“Serviço Nacional de Saúde”, Portuguese Healthcare 
Service) becomes sustainable and that all health professionals - pharmacists, physicians, nurses 
- work together to prevent disease, promote health and treat patients better and better (Ana 
Paula Martins 2016b, 2016). Her point of view follows the rest of the Europe. For instance, the 
“European Pharmacist Forum” released a white paper called “The role of pharmacy in 
supporting the public's health” which states European real examples of how pharmacies make 
the difference in areas such as “Improving adherence to medicines”, “Screening for early 
identification of disease” and “Providing public health services to prevent diseases”. According 
to these facts, the European Pharmacist Forum asks for the  collaboration of health systems and 
governments together with pharmacists in order to improve the pharmacy role on society 
(European Pharmacist Forum, 2015). 
b) The reality of the system 
Portuguese pharmacies went through a huge economic and financial crisis in the past few 
years. Pharmacies were targeted in several economic and legislative measures which either 
increased the sector’s competition and reduced the profitability of the pharmacies: it was 
allowed to sell OTC drugs outside pharmacies (Decree-law 134/2005 of August 16); the price 
of drugs reduced continuously (Decree-law 65/2007 of March 14); it was allowed to make 
discounts on medication (Decree-law 65/2007 of March 14); the property of pharmacies was 
liberalized (Decree-law 307/2007 of August 31) and regressive margins on drugs were 
implemented (the margin decreases as the price increases) (Decree-law 112/2011 of November 
29). 
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In order to react to this new environment, pharmacies had to change their focus and, instead 
of focusing only on selling drugs, they started focusing on patients’ care. On the other hand, 
the SNS is always fighting against limited resources at hospitals and health centers, which are 
in the majority of time with a lot of waiting patients and huge waiting time.  
c) UK example 
At the UK, something similar is already being done: “Community pharmacists are also 
taking on more of the clinical roles that have traditionally been undertaken by doctors, such as 
the management of asthma and diabetes as well as blood pressure testing. They also help people 
give up smoking, alter their diets to make them healthier and advise on sexual health matters” 
(Royal Pharmaceutical Society a, 2016). Moreover, one of the career options for pharmacy in 
the UK is Primary Care Pharmacist, which has an important role on “preventing people from 
becoming ill and encouraging healthier lifestyles so as to keep them out of hospital” (Royal 
Pharmaceutical Society b, 2016).  
There are some entities such as the American Heart Association, the British National Health 
Service, the Canadian Medical Association along with the Canadian Pharmacist Association, 
and others that are valuing the role of the pharmacist in preventive medicine (Tsuyuki et al., 
2002). There is evidence of successful preventive health programs in chronic diseases executed 
by pharmacists (Tsuyuki et al., 2002).   
d) More about biochemical and physiological measurements 
Measuring biochemical and physiological parameters has long been part of functions of a 
pharmacy. In the past, pharmacies had clinical laboratories incorporated but, with the change 
of the legislation in the past century, they had to be separated. Since then, only simple 
measurements with capillary blood are made at the pharmacy (the most common are 
cholesterol, glycaemia, uric acid, hemoglobin, PSA (prostate-specific antigen), blood pressure 
and BMI (body mass index)). This blood is obtained through a small puncture on the finger. 
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Then, specific and calibrated devices are used in order to get reliable results. Usually, the 
initiative to make these measurements come from patients when they think that something may 
not be normal with their health. Only a few people have regular monthly measurements. These 
measurements can be made by a pharmacist or by a pharmacy technician, and they should be 
made on a reserved area of the pharmacy (there is usually a patient’s cabinet), so that patients 
feel comfortable. The consultations of the study followed the structure of a usual 
pharmaceutical consultation. They started with a brief talking about how the patient felt, if 
he/she had gone to the doctor and if there were any doubts related to the medication or to any 
health-related topic. At this point, the changes on medication were registered, if applicable. The 
measurement of the parameters started by blood pressure, as this was the moment were the 
patient was less anxious (after the conversation and before the puncture of the finger). Then, 
the other measurements were made. We analyzed the results of parameters and we made the 
counseling according to DGS’ guidelines or, if needed, the referring to the doctor. To finish 
consultations, we applied the questionnaire(s).  
 As mentioned before, these services are already made at the pharmacy and have the purpose 
of following up patients and evaluating the need to referring to a medical consultation. Usually, 
each biochemical parameter is specific for a certain organ or disease and its variation works as 
an indicator for a certain condition. In the “Glossary”, there is a brief characterization of the 
biological and physiological parameters measured, as well as an explanation of the values that 
are considered as normal, is reported. The importance of these parameters is presented below. 
i) Cholesterol – The excess of this molecule greatly affects human health as it is involved in 
several conditions such as atherosclerosis (see “Glossary”). The fact that it is produced 
endogenously makes cholesterol levels very difficult to control without medication. The 
pharmacy can play an important role either in controlling its values and in the premature 
detection of high levels of cholesterol. The pharmacist can counsel non-pharmacologic 
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therapeutics such as the adoption of a healthy lifestyle, through the loss of excess weight and 
regular exercise. Studies show that pharmacies have an important role in helping high-risk 
patients to control the levels of cholesterol (Tsuyuki et al., 2002) (Simpson et al., 2001). 
ii) Glycaemia –The most common disease related to glucose levels is diabetes (see “Glossary”). 
The regular measurement of glucose allows predicting any inadequate adherence to medication 
regimens.  Studies show that, at pharmacies, the education of patients about their medication 
and about the importance of the correct adherence to the treatment, allied with glycemic control, 
lead to an improvement in diabetes management (Farsaei et al., 2011) (Butt et al., 2016) 
(Alhabib et al., 2014).  
iii) BMI (Body mass index) –This ratio does not measure directly body fat and it does not give 
information about fat distribution either.  Moreover, this index has two limitations. The first 
one is the overestimation for athletes that have a higher muscular mass: as the majority of the 
weight comes from muscle, the person has lower CV risk than the BMI calculate.  The second 
one is the underestimation in elderly or people with physical disability, because usually people 
loose muscle as they get old or due to some conditions: as the majority of the weight comes 
from fat, the person has more CV risk than the BMI calculate.  
iv) Abdominal circumference - It is proved that it is much more dangerous when the fat is in the 
abdominal area than when it is in any other location (Fujioka et al., 1987). The abdominal fat 
determines the risks of developing certain conditions such as cardiovascular disease and type 2 
diabetes (Després, 1993). Studies have shown that either abdominal circumference and BMI 
work as indicators for the distribution of body fat and are associated with metabolic and 
cardiovascular diseases (Janssen et al., 2004) (Zhu et al., 2004) (Rezende et al., 2006), namely 
hypertension (Sarno and Monteiro, 2007). These parameters can have different applicability 
that goes from the need for changing weight, to the evaluation of the cardiovascular risk or the 
monitoring of chronic diseases such as diabetes or hypertension (DGS a, 2013). The pharmacy 
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has an important role in evaluating BMI and abdominal circumference and in following its 
patients according to their needs. 
v) Blood pressure – When we are towards high blood pressure, we call it hypertension. 
Hypertension is responsible for premature morbidity and mortality: “It represents a major risk 
factor for ischemic and hemorrhagic stroke, myocardial infarction, heart failure, chronic kidney 
disease, cognitive decline and premature death” (Williams, 2011). It is a very difficult disease 
to manage. In the majority of times the cause is unknown, which makes the treatment more 
difficult. However, even a small decrease in blood pressure brings great results: studies show 
that a decrease of 10 mm Hg in systolic blood pressure decreases the episodes of stroke in 41% 
(Law et al., 2009), and a decrease of 5 mm Hg  in systolic blood pressure may decrease stroke 
mortality by 14% and coronary mortality by 9% (Stamler et al., 1989). Moreover, for values 
from 115/75 mmHg, cardiovascular risk doubles each time systolic blood pressure increases 20 
mmHg and diastolic blood pressure increases 10 mmHg (DGS a, 2011). Studies show that the 
pharmacist following hypertensive patients succeed on a better control of the blood pressure. 
Patients improve their knowledge about the disease and how to treat it and recognize with high 
satisfaction the pharmaceutical service (Gums et al., 2015) (Nemerovski et al., 2013). The 
higher the contact between the pharmacist and the patient, the lower the diastolic blood pressure 
achieved (Zillich et al., 2005). Another area of intervention of the pharmacist is patient’s 
lifestyle. These interventions should be integrated on the treatment of the disease and the main 
important areas are the adoption of a balanced diet, the practice of regular physical exercise, 
weight control, the restriction of excessive alcohol consumption, reduction of salt intake and 




As mentioned before, this study started with the objective of measuring the possibility to predict 
changes on patients’ medication and/or health condition based on the evaluations that can be 
made at pharmacies. However, as no clear conclusions could be taken due to its limitations of 
duration and sample size, it became interesting to look at the problem from a different 
perspective and understand how patients valued consultations (more detailed information on 
“Introduction”). It is important to notice that, according to Section II of the Code of Ethics of 
the Portuguese Order of Pharmacists, pharmacists are bound by professional secrecy 
concerning all facts that they have knowledge in the exercise of their profession, with the 
exception of the cases provided by law.  It is also important to notice that the objective of this 
study was never to substitute the doctor but to work in association with him instead.  
b) Methods 
i) Setting: The settings for this study were two community pharmacies in Alentejo, Portugal. One 
located in Beja and the other one located in Serpa. As they were part of the study, consultations 
to patients were unpaid. All patients signed an informed consent in order to participate in the 
program. The data collected was confidentially treated. 
ii) Participants: Patients were selected between the pharmacies’ clients that entered at the 
pharmacy between the 15th and the 19th of February 2016, and that had, at least, one of the 
following diseases: hypertension, diabetes, hypercholesterolemia or eating disorder. We 
approached every patient and the ones who had one of the required diseases and accepted the 
study were automatically included. This selection is considered random once we had no choice 
about who entered the pharmacy on those days. Sixty six patients from the two pharmacies 
were selected: 31 at Serpa and 35 at Beja (approximately 28% and 25% of the patients 
approached, respectively). The patient was considered eligible when she/he entered the 
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pharmacy to buy her/his own medication related to one of these diseases. Patients were given a 
code according to the position of enrolment (1, 2, …, 35) and the city of the pharmacy (S=Serpa 
and B=Beja). 
iii) Intervention: The study consisted on three pharmaceutical consultations (see consultation 
form on Appendix 1 and “Introduction” for more detailed information about consultations and 
questionnaires).  
iv) Design: This study is considered a case study. 
v) Inclusion criteria: As explained in the section “Participants”, patients were selected for the 
study based on their health condition. In order to be included in data analysis, patients had to 
attend all three consultations. 
vi) Study timeline: Both pharmacies started on February 2016 and finished on April 2016.  
vii) Data sources: Data was obtained during the consultations. At the first consultation, 
pharmacists registered demographic data from patients as well as their medication (patients 
were asked to bring the boxes of every pill they were taking). In the following consultations it 
was only registered the medication changes, if any. Clinical data was collected from the results 
of biochemical and physiological tests. The other data (questionnaires) was collected at each 
consultation with the help of the pharmacist. This method was chosen as some patients were 
not able to read and the adopted procedure ensures uniformity of situations. 
viii) Data analysis: In order to make the analysis, the data from both groups (Serpa and Beja) were 
combined so that we get a bigger sample.  
c) Results 
Regarding participants, there were 9 who drop out, meaning that only 57 patients finished 
the study. The reasons given by patients when we called to remember consultations included 
impossibility of scheduling (6 patients), a broken leg (1 patient) and lack of interest in 
consultations (2 patients). The average age was 67,9 years and approximately 72% of 
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participants were women. Table 7 (appendix 2) presents the main characteristics of participants. 
Approximately 89% of patients had 50 or more years and the more common chronic diseases 
were hypertension (64,9% of participants) and hypercholesterolemia (59,6% of participants).  
In what concerns physiological and biochemical parameters, average values per 
consultation, as well as standard deviation, maximum and minimum values are presented on 
table 8, appendix 2. It is important to understand that the average has the disadvantage of being 
very sensitive to extreme values. Thus we need to analyze not only the average, but also the 
standard deviation, the maximum and the minimum. The standard deviation gives us how 
dispersed data is relatively to the average. For instance, if the average value is getting closer to 
optimal values and the standard deviation is decreasing, it means that the data is funneling and 
results are positive. Otherwise, if the average is getting closer to optimal values but the standard 
deviation is increasing, it means that there are values that are getting closer the optimal but 
others are deviating. Thus, it is important to analyze the data as a whole. In this case, as we 
have no significant changes on values and we cannot observe a tendency, no conclusions can 
be taken. The detailed distribution of patients, according guidelines, per parameter per 
consultation is on table 9, appendix 2. We will now analyze each parameter and its evolution 
(more detailed on graphics 1 to 57, appendix 3 and 4). 
• BMI: we can observe that the percentages of patients with normal BMI (20%), pre-obesity 
(45%) and obesity (35%) have only slight variations. We had no participants with BMI lower 
than 18,5 (thinness).  
• Abdominal circumference: this parameter has different reference values for man and 
women, which required separated analysis. The majority of participants (approximately 90% 
of women and 50% of man) had their abdominal circumference considered as “greatly 
increased” by the guidelines (see “Abdominal Circumference” on “Glossary”). 
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• Blood Pressure: as mentioned before, 65% of patients had hypertension as one of the 
diagnosed chronic diseases. Regarding systolic blood pressure, 51% to 65% of participants 
presented values at levels of hypertension, whereas for diastolic blood pressure only 3% to 
16% of participants reached hypertension values.  
• Glycaemia: among participants, 28,1% were already diagnosed with diabetes. When 
analyzing results, we verified that around 80% of patients had glycaemia values within the 
normal range. We only had two patients in hypoglycemia (first consultation). We can 
observe that glycaemia values did not change much in time.  
• Cholesterol: as mentioned before, almost 60% of patients had diagnosed 
hypercholesterolemia. Analyzing results, 35% (first consultation) to 49% (third 
consultation) of participants presented normal value of cholesterol.  
Analyzing now the EQ-5D questionnaire, if we look at the 5 different dimensions (table 
10, appendix 5), we can observe that the dimensions Mobility (MO), Self-care (CP) and Usual 
Activities (AH) have the majority of results on level 1 (no problems). Yet dimension 
Pain/Discomfort (DM) has the majority of results at level 2 (some problems), and dimension 
Anxiety/Depression (AD) has its results almost equally divided between level 1 and 2. In order 
to analyze the EQ-5D, it is necessary to apply the formula V=1-α-MO–CP–AH–DM– AD–N3, 
in which “V” represents the health state; 1 represents the value of the perfect health and is used 
to rescale the final result on the interval from 0 to 1; α is a constant that represents the non-
coincidence of the value of any dimension to level 1; N3 is a constant which represents the 
presence of level 3 in any dimension and variables MO, CP, AH, DM and AD assume the values 
given by the table 11, appendix 5 for the respective level of any dimension (Ferreira et al., 
2013). Study’s average “V” (health state) is 0,667. Analyzing results of the three phases (more 
detailed on appendix 6, sheet “EQ-5D”), we can observe that the average subjective health state 
has improved 0,001. The dimensions Mobility and Pain/Discomfort had an average 
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improvement of 0,002 and 0,006, respectively. All the other 3 get worse: Self Care and Usual 
Activities decreased on average 0,002 and Anxiety/Depression decreased, on average, 0,007.  
Looking at the results of the EQ-VAS thermometer, we can observe an increase of 1,8 
points on average subjective general health state (appendix 6, sheet “EQ-5D”). 
Finally, in what concerns the final questionnaire (appendix 6, sheet “Final questionnaire”), 
when faced with questions about how patients felt that the consultation was beneficial to 
understand and deal with their diseases, how they felt that these consultations were important 
and how they trusted on the pharmacy and the pharmacist, participants’ answers were, on 
average, higher than 4,3 on a scale from 1 (“Completely disagree”) to 5 (“Completely agree”). 
When asked about how important the measurement of each parameter was, respondents 
classified, on a scale from 1 (“Not important”) to 6 (“Very important”), as presented on table 
1: 
Cholesterol and blood pressure were considered as the most important by patients while 
height/weight were classified as the less important. When asked if they were willing to pay for 
consultations, 77% of respondents gave a positive answer and, when faced with values, the 
results were the ones presented on table 2. From the 13 respondents that were not willing to pay 
for consultations, 9 (≅69%) would pay if the state copays, even though the values proposed as 
possible contribution by patients were the same in both questions. The amount that patients 
were willing to pay with the State’ copayment is presented on table 2. Table 3 describes the 
reasons why patients were not willing to pay for consultations, being the main reason the fact 
that the money is needed for other expenses. 
Table 1 - Importance of each parameter measurement 
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Finally, 100% of respondents would recommend this consultation to a friend for five euros, 
even the ones that were not willing to pay for it. All results are detailed on appendix 6.  
d) Discussion 
The results of parameters did not show significant differences between consultations of the 
same patients. These results show a stable health on patients being followed at consultations. 
However, we can not make conclusions about what would have happened if no following was 
being made. Regarding BMI and Abdominal Circumference, unless some rigorous diet was 
being made or the patient had some condition that affected weight, these parameters would 
hardly have substantial changes in three months. Blood pressure is a parameter that is very 
sensitive to external factors, such as anxiety and air temperature (the blood pressure decreases 
when the temperature increases). These are some of the reasons why one isolated measure 
cannot be diagnosis of hypertension. In order to analyze blood pressure, consultations should 
be more frequent for patients with high values. Glycaemia is usually a parameter that is within 
the range of normal values once either hypo or hyperglycemias have associated symptoms, 
making patients look for the doctor. The group that needs more careful attention is diabetic 
patients. The patients that we had with glycaemia values considered as diagnosis of diabetes 
were only diabetic people. We had some patients with pre-diabetic values and no diagnosed 
disease, which made important the repetition of the test and the eventual referral to the doctor. 
One of these patients was diagnosed with diabetes, by his doctor, one month after the beginning 
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of the study (participant 6S). Cholesterol, unlike glycaemia, is a parameter that is not associated 
with any symptoms. This is the reason why so many patients are across the “red line”. We can 
observe a decrease of 22,4 points on average cholesterol during the study. It would be 
interesting to understand if this improvement on cholesterol values is related with the 
pharmacist counselling people to change their habits (eating and physical activity).  
Regarding EQ-5D questionnaire, results showed only little improvement between 
consultations, which can be related to the fact that there were no significant changes on health 
state. If we look at Thermometer results, we can also observe little improvement on the 
subjective self-assessment which is, in principle, related with the slight increase on EQ-5D 
results. 
The Final questionnaire showed that, despite the fact that no significant improvements 
happened on general health state, patients valued these consultations and were willing to pay 
for them. It is interesting that all participants, even the ones that would not pay for consultations, 
would recommend a friend to pay. This means that they either value these consultations or that 
they believe that their friends would. The majority of patients were willing to pay less than €5 
euros. Considering €1500 as an average salary for a pharmacist and €3,30 the costs of the 
material used to measure parameters (glucose and cholesterol strips, gloves and lancet), the 
costs of a 15 minutes’ pharmaceutical consultation is €5,64. Thus, the price that patients were 
willing to pay would barely cover the costs. When looking at the questionnaires’ results we 
cannot ignore that some bias can exist once the questionnaires were made face-to-face by the 
pharmacist. This could intimidate the patient to respond that she/he did not consider 
consultations important or the pharmacist as a trustable health professional. The fact that 100% 
of patients would recommend the consultation to a friend provides a cross-check. In other 
words, if the patient claims needing the money for other expenses, this could mean that she/he 
does not see consultations as that important but is intimidated to say it. However, the fact that 
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she/hhe would recommend them to a friend can show that they see some value in consultations. 
In the other hand, when someone is being asked a question, there is a tendency for answering 
in the interviewer’s benefit, even if that is not true. This means that patients could have 
answered that they would recommend consultations to avoid embarrassment by telling the truth.   
It is also important to look at results and understand, from a manager point of view, 
implications and benefits that these consultations would have. On the one hand, it would be an 
added value to the pharmacy. There are no pharmacies on the region making consultations, 
which would be a differentiation factor. Pharmacies would become top-of-mind in the region 
for professionalism and competence. On the other hand, these consultations would bring a great 
responsibility for the pharmacists: continuous learning and training of the pharmacists would 
be needed, which would have some costs associated. Moreover, and maybe the most difficult 
change, would be the scheduling. It is very difficult to schedule an hour with patients and the 
pharmacist to be available at that time. The solution would be to limit consultations to the hours 
with less work at the pharmacy (between 2pm and 3pm) and redistribute some tasks of the 
pharmacist by the other workers of the pharmacy. Regarding the amount to charge for 
consultation, if it is possible to organize the team in a way that the pharmacist is available, the 
opportunity cost of being at the consultation is zero, so it can be charged the €5 that the majority 
of patients are willing to pay. However, if the pharmacist has other tasks to do at that hour, it is 
necessary to calculate their opportunity cost and understand if patients would be willing to pay 
that price. 
e) Limitations 
This study presented a few limitations. The first one was soon detected when I started trying 
to schedule the consultations with patients. It turned out being so hard to schedule that it became 
difficult to implement the four-week interval between consultations. This first limitation made 
impossible to conclude the fourth phase of the study. The second limitation was related to the 
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time spent at each consultation: each patient took around 15 minutes, which makes a total of 
900 minutes or 15 hours per month. This means that during the time that the pharmacist was 
doing the consultations she/he could not be doing her/his job. I had to redistribute functions by 
other workers with the problem that one of the teams was with two workers on a sick leave and 
both teams were with workers on holidays. The whole team had to adjust and work harder. The 
third limitation of the study was its duration: three months is very few time to detect changes 
on the health of people that is stable with the medication. 
f) Conclusion 
This study had the objective to understand if it would be beneficial for either pharmacists, 
pharmacies, healthcare system, doctors and patients the use of community pharmacies to 
decrease the affluence to emergency services. The results of this study were not conclusive due 
to its limitations: difficulty of scheduling pharmaceutical consultations, reorganization of tasks 
with the pharmacy team and the fact that either the sample (57 patients) or the duration (3 
months) of the study were small. However, through the implementation of a final questionnaire, 
it was possible to understand that patients felt these consultations as useful and that they were 
willing to pay for them. In fact, 100% of patients (including the ones that were not willing to 
pay) would recommend a friend to pay €5 for a consultation. This showed that patients valued 
this service. I would suggest the application of this study in a bigger number of pharmacies for 
a period of, at least, one year to understand if a cause-effect relationship can be made.  
Looking from the point of view of the pharmacy’ manager, the implementation of these 
consultations requires some adjustments. Firstly, it is important to reorganize. Secondly, these 
consultations should be scheduled at the hour of lowest traffic at the pharmacy so that the team 
is freer if unexpected events occur. Thirdly, it is important to understand how much it should 
be charged for consultations. Making this in a way that does not harm the daily work, it would 
increase pharmacy recipes, even charging the €5, once the opportunity cost of not doing it is 
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zero. The manager has to balance how consultations can benefit the pharmacy (in terms of 
clients trust and marketing) and how much money is she/he losing with each consultation. 
Making these calculations, the manager opt by implementing or not the service. 
It is very important to notice that the objective of this study was not, at any point, to 
substitute the doctor. The objective is to detect “red lights” on a patient’s health in order to refer 
her/him to the doctor to get a medical evaluation before the situation gets worse, which could 
require going to the emergency services. The goal is that the National Health Service works 
together and doctors and pharmacists increase their communication in order to improve the 
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• AD – Anxiety/Depression 
• BMI – Body Mass Index 
• CV - Cardiovascular 
• ES – Emergency Services 
• HRQOL – Health Related Quality of Life 
• MO – Mobility 
• OECD – Organization for Economic Cooperation and Development 
• OTC – Over-the-counter  
• PD – Pain/Discomfort 
• SC – Self-care 
• SNS – Portuguese Healthcare Service (“Serviço Nacional de Saúde”) 
• UA – Usual activities 
Glossary 
• Abdominal circumference - measure of the perimeter of the abdomen. This measure should 
be made with a tape-measure around the middle after breathing out (DGS a, 2013). The 
reference values are (DGS a, 2013) (DGS, 2004): 
  Table 4 – Abdominal circumference reference values 
• Atherosclerosis - systematic condition that consists on the constriction of arteries with fat, 
reducing the blood flow and improving the chances of a clot formation that can lead to 
peripheral vascular disease (legs), myocardial infarction or stroke. 
• Blood pressure - Pressure that the blood applies to the vessels. According to guidelines, 
hypertension is defined as persistent elevation in various measurements and on different  
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occasions of systolic blood pressure (SBP) greater than or equal to 140 mmHg and/or diastolic 
blood pressure (DBP) greater than 90 mmHg (DGS b, 2013). The clinical algorithm/decision 
tree for hypertension diagnosis is de following (DGS b, 2013): 
Table 5 – Blood pressure reference values 
• BMI (Body mass index) - ratio between 
weight (w) and height (h). It is calculated 
trough the formula BMI=w(kg)/ h2(m). 
Usually, the higher the BMI is (the higher 
is the weight for a certain height), the 
higher the risk for metabolic and 
cardiovascular disease. This happens 
because higher weight is associated with higher fat. The DGS interpretation of the results is 
made according to the World Health Organization (WHO) and is presented on table 4 (DGS a, 
2013). 
• Cholesterol – Type of lipid that is obtained either through food either through endogenous 
synthesis. The amount of cholesterol that is synthetized by our organism is enough to cover our 
body needs. Regarding its functions, the cholesterol plays an important role in several essential 
physiological functions, such as the support of the cell membranes, the production of steroid 
hormones, vitamin D and bile. DGS’ guideline 019/2011 (DGS a, 2015) considers as desirable 
a total blood cholesterol level lower than 190 mg/dL for patients with low to medium CV risk 
and lower than 100 mg/dL for patients with high CV risk. 
• Diabetes – metabolic disease characterized by an increased concentration of blood glucose. 
Diabetes can result from excessive release of glucose from the liver cells to the plasma, usually 
Table 6 – BMI reference values 
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due to an abnormality in insulin secretion (type 1 diabetes), or due to an increased resistance of 
the cells to insulin (type 2 diabetes).  
• Glycaemia - The term “glycaemia” refers to the level of glucose (sugar) in the human body. 
The glucose is obtained through the diet and it is important that its levels remain within a narrow 
range so that it avoids either hypo and hyperglycemia. The regulation of these levels according 
to the needs of the body is made thanks to insulin and glucagon that are secreted according to 
the concentration of glucose in the plasma. After the diagnosis of diabetes doctors prescribe 
medication to avoid either hyperglycemias or long term complications such as cardiovascular 
disease that, in 75% of cases, represents the cause of death (DGS b, 2015). 
The diagnosis of diabetes 
cannot be made if only one single 
abnormal value is registered (DGS b, 
2011).  APDP (“Associação 
protectora dos diabéticos 
portugueses” - Protective association 
of Portuguese diabetics) has a simple 
scale (figure 2) that explains the reference values (APDP 2016). This scale was made using 
references as the WHO (world health organization), DGS guidelines (DGS b, 2011), among 
other sources. 
• OTC (Over-the-counter drug) – medication that does not need medical prescription to be 
bought. 
Figure 1 - Glycaemia reference values  
